OsoBio Reaffirms DCAT Partnership Through New Leadership Positions

Albuquerque, NM, December 19, 2013 --(PR.com)-- OsoBio has reaffirmed its long-standing partnership with the Drug, Chemical and Associated Technologies Association (DCAT) by accepting new volunteer leadership positions within the organization.

OsoBio President Milton Boyer will serve as vice president of DCAT’s executive committee in 2014. And Bob Cashman, vice president of business development at OsoBio, will serve as chairman of DCAT’s scholarship funding committee.

“Members direct DCAT’s efforts and events, which not only differentiates DCAT within the drug and chemical industries, but also increases its value proposition for individual participating companies like OsoBio,” Boyer said. “I am honored that my industry peers chose me to serve in this capacity for DCAT and am excited about what the year holds in store for all member companies.”

Founded in 1890, DCAT is a premier business development association whose membership consists of companies that manufacture, distribute or provide services to pharmaceutical, chemical, and related industries. Attended by thousands each March, the organization’s DCAT Week® is one of the pharmaceutical industry’s largest and most important educational and networking meetings. This year, Hillary Rodham Clinton, former U.S. Secretary of State, will be the keynote speaker at DCAT Week’s annual dinner.

OSO BioPharmaceuticals Manufacturing, LLC, is a contract manufacturing organization (CMO) that specializes in delivering injectable sterile liquid, suspension and lyophilized biologic and pharmaceutical products to the pharmaceutical industry. Our company offers significant knowledge and experience in late-phase clinical products and successfully taking them to commercialization.

In the history of our Albuquerque, N.M., facility, OsoBio has manufactured more than 250 distinct commercial presentations in every major therapeutic category. The U.S. Drug Enforcement Administration (DEA) has granted OsoBio registrations for Schedule II-V controlled substances.

OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects. To learn more about our company and the value we offer clients, visit OsoBio dot com.